Product Description
ST-501 is a drug candidate from Biogen for the treatment of tauopathies including Alzheimer's and Parkinson's Diseases. (Sourced from: https://investors.biogen.com/news-releases/news-release-details/biogen-and-sangamo-announce-global-collaboration-develop-gene)
Mechanisms of Action: Gene Therapy, ZFN
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: Eastern America
Company CEO: Michel Vounatsos
Additional Commercial Interests: Sangamo
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/11/2025 |
News Article |
Pennsylvania Small Businesses and Organizations Speak Out Against Senate Bill 756 |
|
10/11/2023 |
PubMed |
SOD1 is a novel prognostic biomarker of acute kidney injury following cardiothoracic surgery. |
|
11/03/2022 |
PubMed |
Non-lactose fermenting Escherichia coli: Following in the footsteps of lactose fermenting E. coli high-risk clones. |
|
06/01/2022 |
PubMed |
Acute interstitial pneumonia and the biology of 3-methylindole in feedlot cattle. |